The company reported a 9% increase in revenue to $205.7 million for the fiscal year
LONDON: Craneware plc (AIM: CRW.L), a leading provider of financial performance solutions for U.S. healthcare providers, reported a 9% increase in revenue to $205.7 million for the fiscal year ended June 30, 2025, driven by continued sales momentum and strategic expansion.
Annual Recurring Revenue rose 7% to $184.0 million, with Net Revenue Retention climbing to 107%, underscoring the company’s robust customer engagement and expansion sales. Adjusted EBITDA grew 12% to $65.3 million, lifting margins to 32%.
Statutory profit before tax surged 52% to $24.0 million, aided by reduced finance costs through improved treasury management. Adjusted basic earnings per share rose 22.5% to 116.1 cents, while diluted EPS increased 21.6% to 114.2 cents.
Craneware also strengthened its balance sheet, with cash and equivalents rising to $55.9 million and bank debt reduced to $27.7 million. Operating cash conversion reached 94% of adjusted EBITDA.
The board proposed a final dividend of 18.5 pence per share, bringing the total annual dividend to 32.0 pence, up 10% from the prior year.
Operationally, the company highlighted strong customer retention above 90%, integration of customer-facing teams, and the transition of Trisus platform revenues to recurring streams. Trisus® Chargemaster earned Microsoft’s “AI for Healthcare” certification and retained its “Best in KLAS” status.
Craneware’s partnership with Microsoft continues to gain traction, with 13 Trisus solutions now available on Azure Marketplace and joint marketing initiatives underway. The launch of Trisus® Assist, an AI-powered assistant for healthcare finance and operations, marks a key innovation milestone.
CEO Keith Neilson said the results reflect “tireless efforts by our team” and reaffirmed confidence in continued growth for FY26, citing high retention, proprietary data assets, and a resilient SaaS model.
The company also secured a new $100 million unsecured revolving credit facility post-period, with an additional $100 million accordion option.